CheezhengTTM(SZ:002287) Xin Lang Cai Jing·2025-09-18 01:24Core Viewpoint - Qizheng Tibetan Medicine has shown stable trading activity with a slight increase in financing buy-ins, indicating investor interest and potential growth in the company's stock performance [1][2]. Financing and Trading Activity - On September 17, Qizheng Tibetan Medicine's stock price remained unchanged at 0.00%, with a trading volume of 95.95 million yuan. The financing buy-in amounted to 10.52 million yuan, while the financing repayment was 8.26 million yuan, resulting in a net financing buy-in of 2.27 million yuan [1]. - As of September 17, the total financing and securities lending balance for Qizheng Tibetan Medicine was 189 million yuan, with the financing balance accounting for 1.21% of the circulating market value, indicating a high level compared to the past year [1]. - The company had no securities lent or repaid on the same day, with a remaining securities lending volume of 5,000 shares and a balance of 137,000 yuan, which is low compared to the past year [1]. Financial Performance - For the first half of 2025, Qizheng Tibetan Medicine reported a revenue of 1.175 billion yuan, reflecting a year-on-year growth of 16.36%. The net profit attributable to shareholders was 358 million yuan, marking a 10.04% increase compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 3.02 billion yuan in dividends, with 905 million yuan distributed over the last three years [3]. Shareholder Information - As of September 10, the number of shareholders for Qizheng Tibetan Medicine was 36,000, a decrease of 0.90% from the previous period. The average circulating shares per person increased by 1.10% to 15,864 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 2.9896 million shares, an increase of 919,900 shares from the previous period [3].